Jung, Mira

Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer's disease

Sung, Y. M., Lee, T., Yoon, H., DiBattista, A. M., Song, J. M., Sohn, Y., Moffat, E. I., Turner, R. S., Jung, M., Kim, J., et al. (2013) · Experimental Neurology

Alzheimer's disease research and treatmentsHistone Deacetylase Inhibitors Research

Cited by 137

In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors

Konsoula, R., & Jung, M. (2008) · International Journal of Pharmaceutics

Histone Deacetylase Inhibitors ResearchDrug Solubulity and Delivery Systems

Cited by 108

Pharmacokinetics–pharmacodynamics and antitumor activity of mercaptoacetamide-based histone deacetylase inhibitors

Konsoula, Z., Cao, H., Velena, A., & Jung, M. (2009) · Molecular Cancer Therapeutics

Histone Deacetylase Inhibitors ResearchEnzyme function and inhibition

Cited by 27

A Mercaptoacetamide-Based Class II Histone Deacetylase Inhibitor Increases Dendritic Spine Density via RasGRF1/ERK Pathway

Song, J. M., Sung, Y. M., Nam, J. H., Yoon, H., Chung, A., Moffat, E., Jung, M., Pak, D. T. S., Kim, J., & Hoe, H.-S. (2016) · Journal of Alzheimer's Disease

Neuroscience and Neuropharmacology ResearchAlzheimer's disease research and treatments

Cited by 18